Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

152P - Role of occupation in patients with non-small cell lung cancer (NSCLC) in Spain: Data from the SCAN study

Date

31 Mar 2023

Session

Poster Display session

Presenters

Juan Carlos Laguna Montes

Citation

Journal of Thoracic Oncology (2023) 18 (4S): S121-S128.
<article-id>elcc_Ch07

Authors

J.C. Laguna Montes1, F. Turrisi2, V. Albarran3, L. González-Aguado3, T. Gorría Puga3, I. Nalda Ariza3, B. Pastor3, M. Potrony3, M. Garcia De Herreros3, F.J. Muñoz I Carrillo3, O. Castillo4, P. Blasco4, R. Reyes3, N. Viñolas5, S. Hijazo-Pechero4, X. Sole4, A. Arcocha3, C. Teixido5, N. Reguart Aransay3, L. Mezquita3

Author affiliations

  • 1 Barcelona/ES
  • 2 Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 3 Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 4 IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona/ES
  • 5 Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 152P

Background

Cancer is the primary cause of work-related death in Europe (52%). Lung cancer (LC) is one of the most common tumors linked to occupational exposure, although the real prevalence and its clinical profile remains unknown. We aim to study the occupations and patient's profile in a real-world data cohort of NSCLC.

Methods

Prospective study of patients (pts) with all-stages NSCLC treated at Hospital Clinic (Spain) between 2020-present. A personal interview was performed to collect demographic, smoking habit, environmental, cancer history and occupation data. Clinical data was collected from medical reports. Up to 4 jobs were collected for each patient, according to the Spanish National Classification (CNO11), including duration/workplace and occupational exposure.

Results

In the first 168 pts enrolled, median age was 67 years (yrs), 60% male, 87% smokers; 62% had stage IV with mainly adenocarcinoma histology (70%); 60% with a driver alteration. Two out of 3 had high education level; 50% were retired at diagnosis. In our area (city center) the main occupations were: commerce [15%] (60% males; 96% smokers), public services [11%] (44% males; 28% smokers) and mechanical engineering [11%] (83% males; all smokers). Diagnosis before 65 yrs was observed in 75% of construction (6) and 100% of agriculture workers (2) vs. 14% in the tourism sector or none in housekeepers. Occupations related to potential carcinogens exposure were exclusively seen in males (construction, industries), with high smoking rates (75–100%). In contrast, health workers were mainly females (71%) and all housekeepers were females, with lower smoking rates (33%-88%). Regardless of the occupation, adenocarcinoma was the predominant histology; with higher ratio of squamous seen in textile, mechanical, metal/chemical sectors (20–37%).

Conclusions

In our preliminary data, differences on occupational profile were identified in NSCLC. Male smokers were observed in occupations with potential exposure to carcinogens. Deeper characterization of occupation and its clinical impact could improve the work-related LC prevention.

Legal entity responsible for the study

Hospital Clinic y Provincial de Barcelona.

Funding

Has not received any funding.

Disclosure

N. Reguart: Financial Interests, Personal, Invited Speaker: MSD, BMS, Roche, Guardant Health, Pfizer, AbbVie, Ipsen, Novartis, AstraZeneca, Eli Lilly, Takeda, Amgen; Financial Interests, Personal, Advisory Role: MSD, BMS, Roche, Guardant Health, Pfizer, AbbVie, Ipsen, Novartis, AstraZeneca, Eli Lilly, Takeda, Amgen. L. Mezquita: Financial Interests, Personal, Research Grant: Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, Inivata, AstraZeneca; Financial Interests, Personal, Advisory Board: Roche, Takeda; Financial Interests, Personal, Training: Bristol Myers Squibb, Takeda, Foundation Medicine, Janssen; Financial Interests, Personal, Other, Travel/Accommodation: Roche, Takeda, Bristol Myers Squibb, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.